Dateline City:
WHITEHOUSE STATION, N.J.
RAGWITEK is the First and Only FDA Approved Sublingual Allergen Immunotherapy Tablet Indicated for the Treatment of Short Ragweed Pollen Allergies
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that the U.S. Food and Drug Administration (FDA) has
approved RAGWITEK (Short Ragweed Pollen Allergen Extract) Tablet for
Sublingual Use (12 Amb a 1-U).
Language:
English
Contact:
MerckMedia Contacts:Pamela Eisele, 267-305-3558Robert Consalvo, 908-423-6595orInvestor Contacts:Carol Ferguson, 908-423-4465Justin Holko, 908-423-5088
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more